Equity Field Notes from temporal sources

[DanWebzster]

BIOAF is focused on blood-brain-barrier (BBB) penetrating technology that can be attached to existing therapeutics.

The MedImmune division of AZN has independently validated their platform

The problem is that the company only has a cash runway into early 2019, leaving them short of the ability to initiate a Ph1 study for their lead program.

Presently, BIOAF is preparing for a Pre-IND meeting for its lead program, HER 2+ Brain Metastases therapy.

The easiest solution to financing the company into the clinic would be a NASDAQ IPO. To qualify, the company was reverse split and raise capital to meet NAZ requirements.